1,916 material Form 8-K filings that 1,609 companies we cover made with the SEC in July 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Innovative Eyewear, Inc. (Nasdaq: LUCY) agreed on July 8, 2026 to induce holders to exercise 2,200,544 existing warrants for cash at a reduced price of $1.35 per share, down from $2.60. In exchange, the company will issue new unregistered Series J warrants for up to 6,601,632 shares, and gross proceeds of about $3.0 million are expected before placement agent fees and expenses, with closing on July 9, 2026. The deal brings in cash but adds potential dilution for shareholders through the new warrants and placement agent warrants.
2,200,544 existing warrants exercised for cash at a reduced $1.35 per share, versus an original $2.60 exercise price
New Series J warrants cover up to 6,601,632 shares at a $1.10 exercise price, sold at $0.125 per warrant
Gross proceeds of approximately $3.0 million before fees; the company cites working capital and general corporate purposes as the intended use
H.C. Wainwright & Co. is placement agent, with a 7.5% cash fee plus a 1.0% management fee and warrants for up to 165,041 shares at $1.6875; the offering closed July 9, 2026
Northern Technologies International reported third-quarter fiscal 2026 net sales up 12.6% to a record $24,216,000, but swung to a net loss attributable to NTIC of $263,000, or $0.03 per diluted share, from net income of $122,000 a year earlier. Management said higher raw material costs and pricing pressure in its Natur-Tec business cut gross margin by about 477 basis points, and it expects improved gross margin and profitability in the fourth quarter.
Gross profit fell to 33.6% of net sales, down 477 basis points year over year.
Nine-month net loss attributable to NTIC was $61,000, or $0.01 per diluted share, compared with net income of $1,117,000 a year earlier.
ZERUST oil and gas net sales rose 72.3% to $2,219,000 in the quarter.
A non-binding letter of intent dated May 26, 2026 would sell the Beachwood, Ohio facility for $1,150,000 in cash; the sale is expected to close in fiscal 2027.
ENDRA Life Sciences received a Nasdaq notice on July 8, 2026 that it has regained compliance with the $2,500,000 minimum stockholders' equity requirement, after the Staff flagged a shortfall in its 2025 annual report. The company will be under a Discretionary Panel Monitor for one year from July 1, 2026, and if it falls out of compliance again within that period, it could face delisting without a cure period.
Nasdaq Staff letter dated April 20, 2026 cited stockholders' equity below the $2,500,000 minimum, based on the 2025 Form 10-K
Company requested a Nasdaq Hearing Panel hearing on April 27, 2026; hearing held May 28, 2026
On July 8, 2026 Nasdaq notified the company it regained compliance
One-year Discretionary Panel Monitor runs from July 1, 2026; a new deficiency could lead to a Delist Determination Letter and possible delisting
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.